Pharmacyclics: Is it Time to Take Profits?
Pharmacyclics (PCYC) has been a long-term idea for us, and a profitable one at that. But since August when I...Premium
It’s only Monday and Biopharma Deals are already Dominating the Newsflow
Healthcare investors will be well-aware of Valeant's (VRX) $10 billion acquisition of Salix Pharmaceuticals (SLXP), announced over the weekend, but...Read Now